Two-year intermittent exposure of a multiwalled carbon nanotube by intratracheal instillation induces lung tumors and pleural mesotheliomas in F344 rats.


Journal

Particle and fibre toxicology
ISSN: 1743-8977
Titre abrégé: Part Fibre Toxicol
Pays: England
ID NLM: 101236354

Informations de publication

Date de publication:
19 05 2022
Historique:
received: 05 03 2022
accepted: 03 05 2022
entrez: 19 5 2022
pubmed: 20 5 2022
medline: 24 5 2022
Statut: epublish

Résumé

A mounting number of studies have been documenting the carcinogenic potential of multiwalled carbon nanotubes (MWCNTs); however, only a few studies have evaluated the pulmonary carcinogenicity of MWCNTs in vivo. A 2-year inhalation study demonstrated that MWNT-7, a widely used MWCNT, was a pulmonary carcinogen in rats. In another 2-year study, rats administered MWNT-7 by intratracheal instillation at the beginning of the experimental period developed pleural mesotheliomas but not lung tumors. To obtain data more comparable with rats exposed to MWNT-7 by inhalation, we administered MWNT-7 to F344 rats by intratracheal instillation once every 4-weeks over the course of 2 years at 0, 0.125, and 0.5 mg/kg body weight, allowing lung burdens of MWNT-7 to increase over the entire experimental period, similar to the inhalation study. Absolute and relative lung weights were significantly elevated in both MWNT-7-treated groups. Dose- and time-dependent toxic effects in the lung and pleura, such as inflammatory, fibrotic, and hyperplastic lesions, were found in both treated groups. The incidences of lung carcinomas, lung adenomas, and pleural mesotheliomas were significantly increased in the high-dose group compared with the control group. The pleural mesotheliomas developed mainly at the mediastinum. No MWNT-7-related neoplastic lesions were noted in the other organs. Cytological and biochemical parameters of the bronchoalveolar lavage fluid (BALF) were elevated in both treated groups. The lung burden of MWNT-7 was dose- and time-dependent, and at the terminal necropsy, the average value was 0.9 and 3.6 mg/lung in the low-dose and high-dose groups, respectively. The number of fibers in the pleural cavity was also dose- and time-dependent. Repeated administration of MWNT-7 by intratracheal instillation over the 2 years indicates that MWNT-7 is carcinogenic to both the lung and pleura of rats, which differs from the results of the 2 carcinogenicity tests by inhalation or intratracheal instillation.

Sections du résumé

BACKGROUND
A mounting number of studies have been documenting the carcinogenic potential of multiwalled carbon nanotubes (MWCNTs); however, only a few studies have evaluated the pulmonary carcinogenicity of MWCNTs in vivo. A 2-year inhalation study demonstrated that MWNT-7, a widely used MWCNT, was a pulmonary carcinogen in rats. In another 2-year study, rats administered MWNT-7 by intratracheal instillation at the beginning of the experimental period developed pleural mesotheliomas but not lung tumors. To obtain data more comparable with rats exposed to MWNT-7 by inhalation, we administered MWNT-7 to F344 rats by intratracheal instillation once every 4-weeks over the course of 2 years at 0, 0.125, and 0.5 mg/kg body weight, allowing lung burdens of MWNT-7 to increase over the entire experimental period, similar to the inhalation study.
RESULTS
Absolute and relative lung weights were significantly elevated in both MWNT-7-treated groups. Dose- and time-dependent toxic effects in the lung and pleura, such as inflammatory, fibrotic, and hyperplastic lesions, were found in both treated groups. The incidences of lung carcinomas, lung adenomas, and pleural mesotheliomas were significantly increased in the high-dose group compared with the control group. The pleural mesotheliomas developed mainly at the mediastinum. No MWNT-7-related neoplastic lesions were noted in the other organs. Cytological and biochemical parameters of the bronchoalveolar lavage fluid (BALF) were elevated in both treated groups. The lung burden of MWNT-7 was dose- and time-dependent, and at the terminal necropsy, the average value was 0.9 and 3.6 mg/lung in the low-dose and high-dose groups, respectively. The number of fibers in the pleural cavity was also dose- and time-dependent.
CONCLUSIONS
Repeated administration of MWNT-7 by intratracheal instillation over the 2 years indicates that MWNT-7 is carcinogenic to both the lung and pleura of rats, which differs from the results of the 2 carcinogenicity tests by inhalation or intratracheal instillation.

Identifiants

pubmed: 35590372
doi: 10.1186/s12989-022-00478-7
pii: 10.1186/s12989-022-00478-7
pmc: PMC9118836
doi:

Substances chimiques

Carcinogens 0
Nanotubes, Carbon 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

38

Informations de copyright

© 2022. The Author(s).

Références

Environ Int. 2020 Apr;137:105530
pubmed: 32062310
Ind Health. 2010;48(6):783-95
pubmed: 20616469
Oncoimmunology. 2018 Jul 30;7(12):e1474318
pubmed: 30524884
Am Rev Respir Dis. 1975 Jan;111(1):12-20
pubmed: 1111395
Nanotoxicology. 2015 May;9(4):413-22
pubmed: 25030099
Part Fibre Toxicol. 2016 Aug 23;13(1):46
pubmed: 27549627
Toxicol Sci. 2001 Nov;64(1):28-40
pubmed: 11606799
Toxicol Pathol. 2022 Feb;50(2):167-175
pubmed: 34727809
Part Fibre Toxicol. 2020 Oct 15;17(1):48
pubmed: 33054855
Anat Rec. 1997 Sep;249(1):16-23
pubmed: 9294645
Cancer Sci. 2014 Jul;105(7):763-9
pubmed: 24815191
Part Fibre Toxicol. 2011 Jul 22;8:21
pubmed: 21781304
Cancer Sci. 2016 Jul;107(7):924-35
pubmed: 27098557
Acta Anat (Basel). 1997;158(4):255-65
pubmed: 9416356
J Toxicol Sci. 2013;38(4):619-28
pubmed: 23824017
Toxicology. 2010 Mar 10;269(2-3):136-47
pubmed: 19857541
J Natl Cancer Inst. 1977 Mar;58(3):587-603
pubmed: 839555
Toxicol Sci. 2009 Aug;110(2):442-8
pubmed: 19429663
Basic Clin Pharmacol Toxicol. 2019 Feb;124(2):211-227
pubmed: 30168672
Toxicol Sci. 2018 Jul 1;164(1):31-38
pubmed: 29648628
J Immunol Res. 2014;2014:670140
pubmed: 25045719
Nanotoxicology. 2021 Jun;15(5):661-672
pubmed: 33899660
Part Fibre Toxicol. 2010 Oct 04;7:28
pubmed: 20920331
Mutat Res Rev Mutat Res. 2021 Jul-Dec;788:108393
pubmed: 34893158
Ind Health. 2011;49(2):215-20
pubmed: 21173528
J Toxicol Sci. 2009 Feb;34(1):65-76
pubmed: 19182436
Ann N Y Acad Sci. 1972 Dec 29;200:46-65
pubmed: 4574884
Int J Hyg Environ Health. 2005;208(3):201-10
pubmed: 15971859
J Anat. 1994 Dec;185 ( Pt 3):471-9
pubmed: 7649783
Front Immunol. 2021 Jun 14;12:666107
pubmed: 34194430
J Occup Med Toxicol. 2013 Oct 25;8(1):30
pubmed: 24160567
Part Fibre Toxicol. 2013 Aug 09;10:38
pubmed: 23927530
J Toxicol Sci. 2018;43(10):587-600
pubmed: 30298847
J Hazard Mater. 2020 Jul 15;394:122569
pubmed: 32240902
Crit Rev Toxicol. 2017 Nov;47(10):867-884
pubmed: 28937307
Lymphology. 1992 Sep;25(3):120-8
pubmed: 1434787
J Occup Med Toxicol. 2016 Sep 15;11:44
pubmed: 27651824
Environ Health. 2008 Jan 24;7:4
pubmed: 18218073
Part Fibre Toxicol. 2012 Apr 03;9:8
pubmed: 22472194
Cancer Sci. 2021 Jun;112(6):2185-2198
pubmed: 33665882
Cancer Sci. 2012 Dec;103(12):2045-50
pubmed: 22938569
Arch Toxicol. 2014 Nov;88(11):1939-64
pubmed: 25212906
Eur Respir J. 1997 Jan;10(1):219-25
pubmed: 9032518
Am J Pathol. 2011 Jun;178(6):2587-600
pubmed: 21641383
Nanotoxicology. 2016 Nov;10(9):1263-75
pubmed: 27323647
J Clin Biochem Nutr. 2015 Mar;56(2):111-7
pubmed: 25759516
Toxicology. 2010 Oct 29;276(3):143-53
pubmed: 20696199
Part Fibre Toxicol. 2014 Nov 20;11:59
pubmed: 25410479
Part Fibre Toxicol. 2021 Jul 23;18(1):25
pubmed: 34301283
Part Fibre Toxicol. 2010 Mar 22;7:5
pubmed: 20307263
Part Fibre Toxicol. 2016 Oct 13;13(1):53
pubmed: 27737701
J Toxicol Sci. 2008 Feb;33(1):105-16
pubmed: 18303189
Cancer Sci. 2019 Aug;110(8):2485-2492
pubmed: 31265162
Crit Rev Toxicol. 2017 Jan;47(1):1-58
pubmed: 27537422
J Toxicol Pathol. 2020 Jul;33(3):145-151
pubmed: 32764839
J Occup Health. 2018 Jan 25;60(1):10-30
pubmed: 29046510
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):579-90
pubmed: 19822075
J Toxicol Pathol. 2013 Jun;26(2):131-40
pubmed: 23914055
Part Fibre Toxicol. 2019 Sep 2;16(1):34
pubmed: 31477126

Auteurs

Motoki Hojo (M)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan. motoki_hojo@member.metro.tokyo.jp.

Ai Maeno (A)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Yoshimitsu Sakamoto (Y)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Aya Ohnuki (A)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Yukie Tada (Y)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Yukio Yamamoto (Y)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Kiyomi Ikushima (K)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Ryota Inaba (R)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Jin Suzuki (J)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Yuhji Taquahashi (Y)

Center for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.

Satoshi Yokota (S)

Center for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.

Norihiro Kobayashi (N)

Center for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.

Makoto Ohnishi (M)

Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan.

Yuko Goto (Y)

Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan.

Takamasa Numano (T)

DIMS Institute of Medical Science, Aichi, Japan.

Hiroyuki Tsuda (H)

Nanotoxicology Project, Nagoya City University, Aichi, Japan.

David B Alexander (DB)

Nanotoxicology Project, Nagoya City University, Aichi, Japan.

Jun Kanno (J)

Center for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.

Akihiko Hirose (A)

Center for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.

Akiko Inomata (A)

Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.

Dai Nakae (D)

Animal Medical Course, Department of Medical Sports, Faculty of Health Care and Medical Sports, Teikyo Heisei University, 4-1 Uruido-Minami, Ichihara, Chiba, 290-0193, Japan. d.nakae@thu.ac.jp.
Department of Nutritional Science and Food Safety, Faculty of Applied Biosciences, Tokyo University of Agriculture, Tokyo, Japan. d.nakae@thu.ac.jp.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH